FTRE Earnings

FTRE reported its FY2025Q4 earnings on 2026-02-26, showcasing a revenue of 0.00 against an estimate of 648.00M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.16 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following FTRE's FY2025Q4 earnings announcement on 2026-02-26, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, FTRE's stock price tends to shift by an average of +13.59% in the 10 days leading up to earnings and -1.65% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate FTRE’s annual revenue to reach 664.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates Revise Upward by 2.82% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between FTRE's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved Revise Upward by 2.82% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, FTRE's stock price typically moves by +13.59% in the 10 days before its earnings and -1.65% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 664.00M.

The earnings call reveals several positive indicators: a 40% increase in RFP volume from new clients, improved decision-making timelines in biotech, and consistent pricing strategies. The company is focusing on optimizing contracts and achieving operating leverage, with no structural barriers to margin improvement. The CEO's positive surprise regarding workforce morale further supports a positive outlook. However, the lack of 2026 guidance and potential pricing pressures are cautionary notes. Given the market cap, the stock price is likely to react positively, within the 2% to 8% range.